IO-312

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameIO-312
Drug Alias NameIO-312
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4CD3 T-cell engagers
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4T cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesYiming Biomedical Technology (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYiming Biomedical Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A